NASDAQ:CBAY CymaBay Therapeutics - CBAY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.26 +0.46 (+5.90%) (As of 01/30/2023 02:53 PM ET) Add Compare Share Share Today's Range$7.78▼$8.4650-Day Range$3.27▼$8.0652-Week Range$1.67▼$8.46Volume1.15 million shsAverage Volume1.77 million shsMarket Capitalization$699.47 millionP/E RatioN/ADividend YieldN/APrice Target$12.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.33 Rating ScoreUpside/Downside56.3% Upside$12.80 Price TargetShort InterestBearish4.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.94Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.22) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.43 out of 5 starsMedical Sector256th out of 1,049 stocksPharmaceutical Preparations Industry123rd out of 514 stocks 3.6 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.80, CymaBay Therapeutics has a forecasted upside of 56.3% from its current price of $8.19.Amount of Analyst CoverageCymaBay Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.46% of the outstanding shares of CymaBay Therapeutics have been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in CymaBay Therapeutics has recently increased by 1.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 3.9 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CymaBay Therapeutics this week, compared to 1 article on an average week.Search Interest30 people have searched for CBAY on MarketBeat in the last 30 days. This is an increase of 76% compared to the previous 30 days.MarketBeat Follows13 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions73.54% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.22) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CymaBay Therapeutics (NASDAQ:CBAY) StockCymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.Read More Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Stock News HeadlinesJanuary 30, 2023 | finance.yahoo.comCymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesJanuary 24, 2023 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Short Interest UpdateJanuary 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 24, 2023 | americanbankingnews.comBrokerages Set CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Target Price at $11.25January 17, 2023 | finance.yahoo.comHere's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price StrengthJanuary 9, 2023 | markets.businessinsider.comCymaBay, Kaken To Develop And Commercialize Seladelpar In Japan For Primary Biliary CholangitisJanuary 8, 2023 | finance.yahoo.comCymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary CholangitisNovember 23, 2022 | finance.yahoo.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to dateJanuary 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." November 15, 2022 | seekingalpha.comCymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finance.yahoo.comCymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | finance.yahoo.comCymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022November 4, 2022 | finance.yahoo.comCymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022November 3, 2022 | finance.yahoo.comCymaBay Therapeutics to Present at Upcoming Investment ConferencesNovember 1, 2022 | finance.yahoo.comCymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and DevelopmentOctober 13, 2022 | finance.yahoo.comInstitutional investors own a significant stake of 50% in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)October 5, 2022 | marketwatch.comCymaBay Therapeutics Announces Three Presentations at The Liver Meeting(R) 2022October 5, 2022 | finance.yahoo.comIs Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?October 3, 2022 | finance.yahoo.comCymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022October 1, 2022 | reuters.comCymabay Therapeutics IncSeptember 14, 2022 | baystreet.caCymaBay to Host Virtual Analyst Day Next WeekSeptember 14, 2022 | finance.yahoo.comCymaBay Therapeutics Hosting Virtual Analyst Day on September 22August 30, 2022 | finance.yahoo.comCymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?August 24, 2022 | finance.yahoo.comCymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022August 16, 2022 | finance.yahoo.comCymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?August 13, 2022 | uk.investing.comCymaBay Therapeutics Misses Q2 EPS by 2cAugust 12, 2022 | finance.yahoo.comCymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Company Calendar Last Earnings11/14/2022Today1/30/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees59Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.80 High Stock Price Forecast$19.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+55.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.63% Return on Assets-57.26% Debt Debt-to-Equity Ratio1.43 Current Ratio12.20 Quick Ratio12.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book4.28Miscellaneous Outstanding Shares84,681,000Free Float79,939,000Market Cap$699.47 million OptionableOptionable Beta0.19 Key ExecutivesSujal ShahPresident, Chief Executive Officer & DirectorDaniel MenoldVice President-FinanceCharles A. McWherterPresident-Research & DevelopmentDennis D. KimChief Medical OfficerPaul T. QuinlanSecretary & Chief Compliance OfficerKey CompetitorsMersana TherapeuticsNASDAQ:MRSNViking TherapeuticsNASDAQ:VKTXAmneal PharmaceuticalsNYSE:AMRXFulcrum TherapeuticsNASDAQ:FULCMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 8,219 shares on 11/15/2022Ownership: 2.296%Laurion Capital Management LPBought 40,631 shares on 11/15/2022Ownership: 1.908%State Street CorpSold 23,847 shares on 11/15/2022Ownership: 0.399%Algert Global LLCSold 38,854 shares on 11/15/2022Ownership: 0.069%Citadel Advisors LLCSold 100 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CBAY Stock - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price forecast for 2023? 3 brokerages have issued 12-month price targets for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $8.00 to $19.00. On average, they predict the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2023? CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 24.4% and is now trading at $7.80. View the best growth stocks for 2023 here. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $7.80. How much money does CymaBay Therapeutics make? CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $660.50 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090. This page (NASDAQ:CBAY) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.